Comparative Pharmacology
Head-to-head clinical analysis: FILSPARI versus HYDROCHLOROTHIAZIDE VALSARTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FILSPARI versus HYDROCHLOROTHIAZIDE VALSARTAN.
FILSPARI vs HYDROCHLOROTHIAZIDE; VALSARTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FILSPARI (sparsentan) is an endothelin receptor antagonist (ERA) and angiotensin II receptor blocker (ARB) with high affinity for the endothelin type A (ETA) receptor and angiotensin II type 1 (AT1) receptor. It reduces proteinuria in IgA nephropathy by inhibiting endothelin-1 mediated vasoconstriction, inflammation, and fibrosis, and by blocking angiotensin II mediated effects.
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and water reabsorption. Valsartan is an angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to AT1 receptors, causing vasodilation and reduced aldosterone secretion.
200 mg orally once daily, with or without food.
Oral, 12.5-25 mg hydrochlorothiazide / 80-320 mg valsartan once daily. Maximum dose: 25 mg hydrochlorothiazide / 320 mg valsartan per day.
None Documented
None Documented
Terminal half-life ~30 hours in healthy subjects, supporting once-daily dosing.
Hydrochlorothiazide: 6-15 hours (terminal); clinical effect persists due to tubular secretion. Valsartan: 6 hours (terminal); no accumulation with once-daily dosing.
Primarily hepatic metabolism; <1% excreted unchanged in urine. ~59% of dose recovered in feces and ~27% in urine as metabolites.
Hydrochlorothiazide: ~70% renal (unchanged) via tubular secretion; ~30% biliary/fecal. Valsartan: 83% fecal (unchanged); 13% renal (unchanged and metabolites).
Category C
Category D/X
Endothelin Receptor Antagonist / ARB
ARB